{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:45:40Z","timestamp":1767181540394,"version":"build-2238731810"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166290","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T13:30:55Z","timestamp":1478871055000},"page":"e0166290","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease"],"prefix":"10.1371","volume":"11","author":[{"given":"Daniel","family":"Rob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Marek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Dost\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubor","family":"Gol\u00e1\u0148","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"ref1","first-page":"123","article-title":"Fabry disease\u2014Vascular manifestations","volume":"39","author":"D Karetova","year":"2010","journal-title":"Vasa. Verlag Hans Huber"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"SM Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"DI Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2007.11.094","article-title":"Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study","volume":"125","author":"AM Strasak","year":"2008","journal-title":"Int J Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"G Zhao","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med. American College of Physicians"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"RM Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"M Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis. BioMed Central"},{"key":"ref9","first-page":"353","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"DP Germain","year":"2015","journal-title":"J Med Genet. BMJ Publishing Group Ltd"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"XW Wu","year":"1992","journal-title":"J Mol Evol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0891-5849(02)00956-5","article-title":"Structure and function of xanthine oxidoreductase: where are we now?","volume":"33","author":"R Harrison","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"R1014","DOI":"10.1152\/ajpregu.00124.2004","article-title":"Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology","volume":"287","author":"J-M Li","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"P Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"J George","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(81)90232-4","article-title":"Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium","volume":"25","author":"ED Jarasch","year":"1981","journal-title":"Cell"},{"key":"ref16","first-page":"68","article-title":"Changes in xanthine oxidase activity in patients with circulatory failure","volume":"61","author":"ZA Bakhtiiarov","year":"1989","journal-title":"Ter arkhiv"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","article-title":"Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis","volume":"30","author":"P Higgins","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/heartjnl-2014-305683","article-title":"Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial","volume":"100","author":"P Higgins","year":"2014","journal-title":"Heart"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archinternmed.2010.198","article-title":"Gout, Allopurinol Use, and Heart Failure Outcomes","volume":"170","author":"G Thanassoulis","year":"2010","journal-title":"Arch Intern Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial","volume":"375","author":"A Noman","year":"2010","journal-title":"Lancet (London, England)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11255-011-9929-6","article-title":"Allopurinol, uric acid, and oxidative stress in cardiorenal disease","volume":"43","author":"M Riegersperger","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"C584","DOI":"10.1152\/ajpcell.00600.2006","article-title":"Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative\/nitrosative stress","volume":"293","author":"YY Sautin","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/HJH.0b013e3282f240bf","article-title":"Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system","volume":"26","author":"DB Corry","year":"2008","journal-title":"J Hypertens"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1159\/000345509","article-title":"Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations","volume":"121","author":"LG S\u00e1nchez-Lozada","year":"2012","journal-title":"Nephron Exp Nephrol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"UM Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1096\/fj.13-247148","article-title":"Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis","volume":"28","author":"Y-J Choi","year":"2014","journal-title":"FASEB J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehi879","article-title":"Uric acid and inflammatory markers","volume":"27","author":"C Ruggiero","year":"2006","journal-title":"Eur Heart J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1681\/ASN.2005050572","article-title":"Uric Acid-Induced C-Reactive Protein Expression: Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells","volume":"16","author":"D-H Kang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","article-title":"Common and uncommon pathogenic cascades in lysosomal storage diseases","volume":"285","author":"EB Vitner","year":"2010","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"J-S Shen","year":"2008","journal-title":"Mol Genet Metab. NIH Public Access"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jmri.20162","article-title":"Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study","volume":"20","author":"DF Moore","year":"2004","journal-title":"J Magn Reson Imaging"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"GB Biancini","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"YA Zarate","year":"2008","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijcard.2009.03.045","article-title":"Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease","volume":"144","author":"T Palecek","year":"2010","journal-title":"Int J Cardiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/eurjhf\/hfq211","article-title":"Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A","volume":"13","author":"W Machann","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study","volume":"131","author":"MM Givertz","year":"2015","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semnephrol.2011.08.007","article-title":"Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options","volume":"31","author":"W Doehner","year":"2011","journal-title":"Semin Nephrol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1016\/S0002-9149(02)03144-2","article-title":"Role of oxidative stress in atherosclerosis","volume":"91","author":"D Harrison","year":"2003","journal-title":"Am J Cardiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"LK Niskanen","year":"2004","journal-title":"Arch Intern Med. American Medical Association"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2005090949","article-title":"Uric acid and endothelial dysfunction in essential hypertension","volume":"17","author":"C Zoccali","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00392-007-0636-3","article-title":"Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome","volume":"97","author":"O Yiginer","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"W Doehner","year":"2002","journal-title":"Circulation"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.HYP.35.3.746","article-title":"Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension","volume":"35","author":"R Butler","year":"2000","journal-title":"Hypertension"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1681\/ASN.2010111185","article-title":"Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease","volume":"22","author":"MP Kao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"R Schiffmann","year":"2006","journal-title":"Virchows Arch. NIH Public Access"},{"key":"ref46","first-page":"5","article-title":"3-Nitrotyrosine as a biomarker for vascular involvement in Fabry disease","volume":"86","author":"DA Joly","year":"2014","journal-title":"Kidney Int. International Society of Nephrology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semnephrol.2004.09.007","article-title":"Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease","volume":"25","author":"J Kanellis","year":"2005","journal-title":"Semin Nephrol. Elsevier"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"T DeGraba","year":"2000","journal-title":"Ann Neurol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"A Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"MH Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0002-9149(01)02155-5","article-title":"Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease","volume":"89","author":"C Bickel","year":"2002","journal-title":"Am J Cardiol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"H Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cjca.2015.02.018","article-title":"Plasma Uric Acid as a Prognostic Marker in Patients With Hypertrophic Cardiomyopathy","volume":"31","author":"L Zhu","year":"2015","journal-title":"Can J Cardiol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1751-7133.2010.00144.x","article-title":"Uric Acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparison with N-terminal pro B-type natriuretic peptide level","volume":"16","author":"H Kim","journal-title":"Congest Heart Fail"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000150784.92944.9a","article-title":"Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence","volume":"45","author":"J Sundstr\u00f6m","year":"2005","journal-title":"Hypertension"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"PC Grayson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/01.HYP.0000200033.14574.14","article-title":"Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension","volume":"47","author":"Y Iwashima","year":"2006","journal-title":"Hypertension"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis","volume":"61","author":"SY Kim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"RJ Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"G Zoppini","year":"2012","journal-title":"Diabetes Care"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"382918","DOI":"10.1155\/2015\/382918","article-title":"Uric Acid as a Marker of Kidney Disease: Review of the Current Literature","volume":"2015","author":"C Giordano","year":"2015","journal-title":"Dis Markers"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2337\/db12-1814","article-title":"Sugar, uric acid, and the etiology of diabetes and obesity","volume":"62","author":"RJ Johnson","year":"2013","journal-title":"Diabetes"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11906-013-0344-5","article-title":"Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?","volume":"15","author":"Z Soltani","year":"2013","journal-title":"Curr Hypertens Rep"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0170881","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:55:21Z","timestamp":1601178921000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166290"}},"subtitle":[],"editor":[{"given":"John Lynn","family":"Jefferies","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166290","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}